Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?

30.12.24 14:30 Uhr

Werte in diesem Artikel
Aktien

390,40 EUR 0,45 EUR 0,12%

Indizes

PKT PKT

21.012,2 PKT -184,9 PKT -0,87%

19.310,8 PKT -176,0 PKT -0,90%

5.881,6 PKT -25,3 PKT -0,43%

Investors in Vertex Pharmaceuticals Incorporated VRTX need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $145 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.What do the Analysts Think?Clearly, options traders are pricing in a big move for Vertex Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Vertex Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 22% of our Zacks Industry Rank. Over the last 60 days, four analysts have increased their earnings estimates for the current quarter, while five analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $4.14 per share to $4.00 in that period.Given the way analysts feel about Vertex Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.Click to see the trades now >>Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Vertex Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vertex Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Vertex Pharmaceuticals Inc.

Wer­bung

Analysen zu Vertex Pharmaceuticals Inc.

DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
05.03.2018Vertex Pharmaceuticals BuyMaxim Group
01.02.2018Vertex Pharmaceuticals OverweightBarclays Capital
DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
24.10.2016Vertex Pharmaceuticals NeutralH.C. Wainwright & Co.
29.01.2015Vertex Pharmaceuticals HoldMaxim Group
29.01.2015Vertex Pharmaceuticals HoldNeedham & Company, LLC
DatumRatingAnalyst
14.12.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
05.11.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
04.01.2008Vertex Pharmaceuticals DowngradeWachovia Sec
14.12.2006Vertex Pharmaceuticals DowngradeBanc of America Sec.
22.11.2005Update Vertex Pharmaceuticals Inc.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vertex Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"